Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Total Liabilities: 2022-2024

Historic Total Liabilities for Silence Therapeutics (SLN) over the last 3 years, with Dec 2024 value amounting to $68.6 million.

  • Silence Therapeutics' Total Liabilities rose 1968.32% to $72.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.7 million, marking a year-over-year increase of 1968.32%. This contributed to the annual value of $68.6 million for FY2024, which is 29.60% down from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' Total Liabilities is $68.6 million, which was down 29.60% from $97.5 million recorded in FY2023.
  • Silence Therapeutics' 5-year Total Liabilities high stood at $97.5 million for FY2023, and its period low was $95,508 during FY2022.
  • For the 3-year period, Silence Therapeutics' Total Liabilities averaged around $55.4 million, with its median value being $68.6 million (2024).
  • In the last 5 years, Silence Therapeutics' Total Liabilities soared by 101,938.37% in 2023 and then dropped by 29.60% in 2024.
  • Over the past 3 years, Silence Therapeutics' Total Liabilities (Yearly) stood at $95,508 in 2022, then spiked by 101,938.37% to $97.5 million in 2023, then decreased by 29.60% to $68.6 million in 2024.